Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of VV116 in Healthy Chinese Volunteers
NCT05201690Phase 1Completed
- Sponsor
- Vigonvita Life Sciences
- Start
- Dec 2021
- Primary completion
- Jan 2022
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of deuremidevir in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Vigonvita Life Sciences. Primary endpoints: Treatment-Emergent Adverse Events, Laboratory Test Abnormalities and 2 more. Started Dec 2021; status: completed.
02
Drugs
deuremidevir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05201690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05201690.